The effectiveness of N-acetylcysteine in alleviating clinical Symptoms of COVID-19 hospitalized patients at Santa Elisabeth Purwokerto General Hospital, Indonesia

Abstract

Background: COVID-19 has been associated with increased innate immune system activation, leading to increased mucus production, inflammation, and tissue damage. N-Acetylcystysteine (NAC), an antioxidant and mucolytic, has demonstrated potential as a COVID-19 therapy.


Objective: The purpose of this study was to evaluate the effectiveness of NAC on the clinical symptoms of hospitalized COVID-19 patients at Santa Elisabeth Purwokerto General Hospital in Indonesia.


Methods: An observational analytical study design was employed, with data collected from the medical records of hospitalized COVID-19 patients at Santa Elisabeth Purwokerto General Hospital over the period of July 2020 to July 2021. The study included 209 patients who met the eligibility criteria.


Results: The results indicated that the use of NAC affected the clinical symptoms of cough, oxygen saturation (SPO2), and respiratory rate in patients with mild and moderate degrees of COVID-19 patients (p<0.05). However, it was found not to affect patients with severe degrees of the disease (p>0.05).


Conclusion: This study suggests that NAC may be a useful treatment option for patients with mild and moderate COVID-19. Further research is needed to confirm these findings and determine their effectiveness in severe cases.

Published
2023-02-04
How to Cite
EKOWATI, Heny et al. The effectiveness of N-acetylcysteine in alleviating clinical Symptoms of COVID-19 hospitalized patients at Santa Elisabeth Purwokerto General Hospital, Indonesia. Acta Pharmaciae Indonesia : Acta Pharm Indo, [S.l.], v. 11, n. 1, p. 7548, feb. 2023. ISSN 2621-4520. Available at: <https://jos.unsoed.ac.id/index.php/api/article/view/7548>. Date accessed: 14 mar. 2025. doi: https://doi.org/10.20884/1.api.2023.11.1.7548.